Pharmacy Website

FACULTY PROFILE

Marc Sturgill, PharmD
Associate Professor and Chair
Department of Pharmacy Practice and Administration
William Levine Hall, Rm 424
Phone: (848) 445 6828
Email: marc.sturgill@pharmacy.rutgers.edu

Specialty: Pediatrics
Practice site: Robert Wood Johnson University Hospital

Bio

Dr. Sturgill joined the Department of Pharmacy Practice and Administration in July 1992, was promoted to Associate Professor with tenure in July 1998, and was appointed Department Chair in October 2013.  He received a New Investigator Grant from the American Association of Colleges of Pharmacy in November 1994, was the recipient of the Roche Laboratories Clinical Preceptor of the Year Award in May 2001, and the William and Helen Levine Teacher of the Year Award in May 2003, May 2004, and May 2006.

Dr. Sturgill was appointed to the New Jersey Board of Pharmacy in March 2005, serving until March 2014. He was a member of the Adult Clinical Research Center in the Department of Medicine at UMDNJ-Robert Wood Johnson Medical School from July 1992 to January 2005, and was appointed Assistant Director of the newly formed Pediatric Clinical Research Center, in the Department of Pediatrics, in January 2006. Dr. Sturgill continues to hold an adjunct appointment in the Department of Pediatrics at the Rutgers—Robert Wood Johnson Medical School.

Research

Dr. Sturgill’s clinical research interests include the effects of age, disease, and xenobiotics on drug pharmacokinetics, in particular the effect of these variables on the activity of human drug metabolizing enzymes.

Representative Papers/Presentations

Kunvarjee B, Weller A, Shah M, Yen E, Sturgill M. Evaluation of an Institution’s Use of High-Dose Ampicillin for Empiric Treatment of Pediatric Community-Acquired Pneumonia. Forty-Ninth Annual ASHP Midyear Clinical Meeting, Anaheim, California, 2014.

DiMeo R, Uppaluri L, Drachtman R, Savage B, Sturgill M. Analysis of Pulmonary Disease in Pediatric Patients with Sickle Cell Disease. Forty-Seventh Annual ASHP Midyear Clinical Meeting, Las Vegas, Nevada, 2012.

Sison A, Ciaramella C, Weiss A, Gaur S, Sturgill MG. Validation  of  the  Current Use  of Nafcillin and Ceftazidime as Empirical  Combination  Drug Therapy in Pediatric Patients with Febrile Neutropenia Secondary to Chemotherapy. Forty-Sixth Annual ASHP Midyear Clinical Meeting, Anaheim, California, 2011.

Lambert GH, Sturgill MG, Cousins DD. Medication errors. In: Yaffe SJ, Aranda JV, eds. Neonatal and Pediatric Pharmacology, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2004:823-31.

Lambert JD, Lee M-J, Lu H, Meng X, Hong JJJ, Seril DN, Sturgill MG, Yang CS. Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. Journal of Nutrition 2003;133:4172-7.

Boruchoff SE, Sturgill MG, Grasing KW, Seibold JR, McCrea J, Winchell GA, Kusma SE, Deutsch PJ. The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin. Clinical Pharmacology & Therapeutics 2000;67:351-9.

Sturgill MG, Rashidbaigi A, Liao M-J, Zhao X-X, Hua J, Trout R, Knill JR, Grasing KW. Extravascular administration of interferon alfa-n3 increases serum exposure and 2-5(A) synthetase activity. Journal of Clinical Pharmacology 2000;40:606-15.

Sturgill
MG, August DA, Brenner DE. Hepatic enzyme induction with phenobarbital and doxorubicin metabolism and myelotoxicity in the rabbit. Cancer Investigation 2000;18(3):197-205.

Sturgill MG, Seibold JR, Boruchoff SE, Yeh KC, Haddix H, Deutsch P. Trimethoprim/sulfamethoxazole does not affect the steady-state disposition of indinavir. Journal of Clinical Pharmacology 1999;39:1077-84.

Sturgill MG, Drachtman RA, Ettinger AG, Rubin J, Ettinger LJ. The influence of Epstein Barr virus seropositivity on the response to intravenous immune globulin (IVIG) in children with immune thrombocytopenic purpura (ITP). Clinical Pediatrics 1999;38:171-3.

Sturgill MG, Brenner DE, August DA. Augmentation of hepatic doxorubicin extraction with extracorporeal filtration avoids the dose-dependent, non-linear increase in AUC observed with systemic administration. Cancer Chemotherapy and Pharmacology 1998;41:193-200.

Sturgill MG, Lambert GH. Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function. Clinical Chemistry 1997;43:1512-26.

Sturgill MG, Nagabandi SR, Drachtman RA, Ettinger AG, Rubin J, Ettinger LJ. The effect of ABO and Rh blood type on the response to intravenous immune globulin (IVIG) in children with immune thrombocytopenic purpura (ITP). Journal of Pediatric Hematology/Oncology 1997;19:523-5.

Sturgill MG, Grasing KW, Rosen RC, Thomas TJ, Kulkarni GD, Trout JR, Maines P, Seibold JR. Yohimbine elimination in normal volunteers is characterized by both one and two-compartment behavior. Journal of Cardiovascular Pharmacology 1997;29(6):697-703.

Sturgill MG, Huhn RD, Drachtman R, Ettinger AG, Ettinger LJ. Pharmacokinetics of intravenous recombinant human granulocyte colony-stimulating factor (rhG-CSF) in children receiving myelosuppressive cancer chemotherapy: clearance increases in relation to absolute neutrophil count with repeated dosing. American Journal of Hematology 1997;54:124-30.

Balani SK, Woolf EJ, Hoagland VL, Sturgill MG, Deutsch PJ, Yeh KC, Lin JH. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metabolism and Disposition 1996;24(12):1389-94.

Grasing K, Sturgill MG, Rosen RC, Trout JR, Thomas TJ, Kulkarni GD, Maines P, Seibold JR. Effects of yohimbine on autonomic measures are determined by individual values for area under the concentration-time curve. Journal of Clinical Pharmacology 1996;36:814-22.

Huhn RD, Radwanski E, O'Connell SM, Sturgill MG, Clarke L, Cody RP, Affrime MB, Cutler DL. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in normal volunteers. Blood 1996;87(2):699-705.

Huhn RD, Yurkow EJ, Tushinski R, Clarke L, Sturgill MG, Hoffman R, Sheay W, Cody R, Philipp C, Resta D, George M. Recombinant human interleukin-3 enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor in normal volunteers. Experimental Hematology 1996;24:839-47.